Exclusive Summary

• - Approved in the US and all 27 EU countries with a full range of 500 mg, 1 g, 5 g, and 10 g vials, enabling rapid distribution and tender readiness.
• - Listed on the WHO Essential Medicines List and recommended by major guidelines as a standard therapy for serious MRSA infections, ensuring stable hospital demand worldwide.
• - High global burden of MRSA and healthcare-associated infections (about 100–200k MRSA-attributable deaths annually; sepsis ~49 million cases) sustains ongoing IV purchasing.
• - Compared with alternatives such as daptomycin, linezolid, and ceftaroline, vancomycin offers a substantially lower course cost, ideal for price-sensitive and high-volume tenders.
• - US and EU registrations demonstrate quality and compliance, supporting fast access under distribution deals and offering differentiation with 5 g and 10 g pharmacy bulk sizes.